Ruud Dings
Concepts (317)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Angiogenesis Inhibitors | 25 | 2022 | 187 | 4.150 |
Why?
| Proteins | 17 | 2010 | 342 | 2.510 |
Why?
| Neovascularization, Pathologic | 17 | 2022 | 161 | 2.470 |
Why?
| Calixarenes | 7 | 2017 | 9 | 2.020 |
Why?
| Galectin 1 | 8 | 2024 | 21 | 1.880 |
Why?
| Melanoma, Experimental | 6 | 2021 | 45 | 1.880 |
Why?
| Antineoplastic Agents | 14 | 2024 | 1171 | 1.620 |
Why?
| Peptides | 20 | 2017 | 223 | 1.420 |
Why?
| Mice | 47 | 2024 | 5739 | 1.310 |
Why?
| Neoplasms | 14 | 2024 | 1235 | 1.250 |
Why?
| Endothelial Cells | 10 | 2022 | 269 | 1.070 |
Why?
| Animals | 53 | 2024 | 13187 | 1.070 |
Why?
| Lung Neoplasms | 5 | 2024 | 606 | 1.070 |
Why?
| Ovarian Neoplasms | 8 | 2008 | 447 | 0.900 |
Why?
| Gold | 7 | 2023 | 136 | 0.900 |
Why?
| Oxygen | 6 | 2020 | 326 | 0.880 |
Why?
| Cell Line, Tumor | 18 | 2024 | 1403 | 0.830 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 154 | 0.800 |
Why?
| Carcinoma, Squamous Cell | 4 | 2019 | 318 | 0.780 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2021 | 20 | 0.760 |
Why?
| Peptide Fragments | 5 | 2013 | 215 | 0.740 |
Why?
| Mammary Neoplasms, Experimental | 6 | 2015 | 122 | 0.730 |
Why?
| Radiation-Sensitizing Agents | 4 | 2023 | 53 | 0.730 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 268 | 0.720 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 10 | 0.690 |
Why?
| Molecular Targeted Therapy | 2 | 2018 | 119 | 0.680 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 204 | 0.660 |
Why?
| Preservation, Biological | 1 | 2018 | 9 | 0.660 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 78 | 0.650 |
Why?
| Anti-Bacterial Agents | 4 | 2019 | 744 | 0.650 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 116 | 0.640 |
Why?
| Radiation Tolerance | 5 | 2020 | 85 | 0.640 |
Why?
| Galectins | 1 | 2018 | 5 | 0.630 |
Why?
| Metal Nanoparticles | 4 | 2023 | 84 | 0.580 |
Why?
| Hyperthermia, Induced | 3 | 2019 | 117 | 0.570 |
Why?
| Bacteria | 1 | 2018 | 224 | 0.570 |
Why?
| Mice, Nude | 12 | 2019 | 252 | 0.560 |
Why?
| Radiotherapy | 5 | 2021 | 128 | 0.550 |
Why?
| Xenograft Model Antitumor Assays | 11 | 2020 | 211 | 0.530 |
Why?
| Pseudomonas aeruginosa | 2 | 2013 | 72 | 0.500 |
Why?
| Combined Modality Therapy | 11 | 2020 | 637 | 0.450 |
Why?
| Benzofurans | 2 | 2012 | 18 | 0.440 |
Why?
| Cytotoxins | 1 | 2013 | 16 | 0.440 |
Why?
| Pseudomonas Infections | 1 | 2013 | 48 | 0.430 |
Why?
| Cell Proliferation | 10 | 2024 | 1007 | 0.430 |
Why?
| Oxidation-Reduction | 3 | 2024 | 322 | 0.430 |
Why?
| Drug Design | 4 | 2014 | 120 | 0.420 |
Why?
| Endothelium, Vascular | 8 | 2010 | 252 | 0.420 |
Why?
| Carbohydrate Metabolism | 1 | 2012 | 26 | 0.420 |
Why?
| Humans | 44 | 2024 | 49974 | 0.410 |
Why?
| Benzeneacetamides | 2 | 2024 | 13 | 0.410 |
Why?
| Glutaminase | 2 | 2024 | 19 | 0.400 |
Why?
| Neoplasms, Experimental | 4 | 2020 | 114 | 0.400 |
Why?
| Nanostructures | 3 | 2023 | 47 | 0.400 |
Why?
| Bacteremia | 1 | 2013 | 90 | 0.400 |
Why?
| Sesquiterpenes | 3 | 2010 | 90 | 0.390 |
Why?
| Angiostatic Proteins | 1 | 2011 | 1 | 0.380 |
Why?
| Immunity, Cellular | 1 | 2011 | 69 | 0.370 |
Why?
| Molecular Mimicry | 2 | 2007 | 38 | 0.370 |
Why?
| Cell Survival | 8 | 2024 | 600 | 0.360 |
Why?
| Dendritic Cells | 3 | 2021 | 133 | 0.360 |
Why?
| Endothelium | 4 | 2022 | 39 | 0.350 |
Why?
| Carboplatin | 3 | 2024 | 53 | 0.350 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2008 | 989 | 0.340 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2019 | 388 | 0.340 |
Why?
| Immunotherapy, Adoptive | 1 | 2011 | 156 | 0.330 |
Why?
| Apoptosis | 7 | 2024 | 1101 | 0.320 |
Why?
| Cells, Cultured | 8 | 2013 | 1573 | 0.320 |
Why?
| Vascular Endothelial Growth Factor A | 7 | 2022 | 201 | 0.320 |
Why?
| Intercellular Adhesion Molecule-1 | 5 | 2022 | 63 | 0.320 |
Why?
| T-Lymphocytes | 1 | 2011 | 338 | 0.320 |
Why?
| Structure-Activity Relationship | 6 | 2012 | 395 | 0.320 |
Why?
| Polyethylene Glycols | 3 | 2021 | 93 | 0.310 |
Why?
| Mice, Inbred C57BL | 8 | 2021 | 1816 | 0.310 |
Why?
| Phototherapy | 2 | 2019 | 45 | 0.300 |
Why?
| Amino Acid Sequence | 5 | 2012 | 585 | 0.300 |
Why?
| Tumor Cells, Cultured | 6 | 2019 | 465 | 0.300 |
Why?
| Female | 24 | 2020 | 26472 | 0.290 |
Why?
| Drug Resistance, Neoplasm | 2 | 2024 | 308 | 0.290 |
Why?
| Magnetic Resonance Spectroscopy | 5 | 2012 | 244 | 0.280 |
Why?
| Blood Vessels | 4 | 2015 | 72 | 0.270 |
Why?
| Antibodies, Monoclonal | 2 | 2007 | 459 | 0.270 |
Why?
| Disease Models, Animal | 7 | 2020 | 1455 | 0.260 |
Why?
| Molecular Sequence Data | 5 | 2012 | 792 | 0.260 |
Why?
| Nanoparticles | 2 | 2017 | 145 | 0.250 |
Why?
| Cell Division | 7 | 2010 | 292 | 0.240 |
Why?
| Cysteine | 1 | 2024 | 50 | 0.240 |
Why?
| Human Umbilical Vein Endothelial Cells | 3 | 2014 | 90 | 0.240 |
Why?
| Bystander Effect | 1 | 2024 | 26 | 0.240 |
Why?
| Buthionine Sulfoximine | 1 | 2024 | 14 | 0.240 |
Why?
| Nanotubes | 2 | 2021 | 27 | 0.230 |
Why?
| Models, Molecular | 4 | 2024 | 338 | 0.230 |
Why?
| Thiadiazoles | 2 | 2024 | 19 | 0.220 |
Why?
| Flow Cytometry | 2 | 2017 | 476 | 0.210 |
Why?
| Alanine | 3 | 2012 | 42 | 0.200 |
Why?
| Cisplatin | 1 | 2024 | 278 | 0.200 |
Why?
| Protein Binding | 3 | 2012 | 660 | 0.200 |
Why?
| Carcinoma, Renal Cell | 1 | 2022 | 105 | 0.200 |
Why?
| Binding Sites | 2 | 2012 | 374 | 0.190 |
Why?
| Optical Imaging | 2 | 2020 | 25 | 0.190 |
Why?
| Silver | 2 | 2021 | 46 | 0.190 |
Why?
| Polyurethanes | 1 | 2021 | 9 | 0.190 |
Why?
| Kidney Neoplasms | 1 | 2022 | 177 | 0.190 |
Why?
| Radiation | 1 | 2020 | 15 | 0.190 |
Why?
| Forkhead Transcription Factors | 1 | 2021 | 112 | 0.190 |
Why?
| Materials Testing | 1 | 2021 | 58 | 0.190 |
Why?
| Spectrum Analysis | 1 | 2020 | 70 | 0.180 |
Why?
| Biocompatible Materials | 1 | 2021 | 69 | 0.180 |
Why?
| Mice, Inbred BALB C | 5 | 2020 | 304 | 0.180 |
Why?
| Mice, Knockout | 3 | 2012 | 841 | 0.180 |
Why?
| Neoplasm Transplantation | 5 | 2007 | 85 | 0.180 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2021 | 164 | 0.170 |
Why?
| Disease Progression | 3 | 2019 | 825 | 0.170 |
Why?
| Oxygen Consumption | 1 | 2020 | 183 | 0.170 |
Why?
| Lactose | 2 | 2024 | 9 | 0.170 |
Why?
| Specimen Handling | 1 | 2018 | 55 | 0.160 |
Why?
| Spectrum Analysis, Raman | 1 | 2019 | 58 | 0.160 |
Why?
| Immunotherapy | 1 | 2020 | 238 | 0.160 |
Why?
| Drug Delivery Systems | 2 | 2019 | 138 | 0.160 |
Why?
| Biological Assay | 1 | 2018 | 45 | 0.160 |
Why?
| Time Factors | 6 | 2017 | 2903 | 0.160 |
Why?
| Feces | 1 | 2018 | 134 | 0.160 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 56 | 0.150 |
Why?
| Indazoles | 1 | 2018 | 47 | 0.150 |
Why?
| Carbohydrates | 1 | 2018 | 40 | 0.150 |
Why?
| Temperature | 1 | 2018 | 168 | 0.150 |
Why?
| Cell Hypoxia | 4 | 2015 | 82 | 0.150 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 37 | 0.150 |
Why?
| Tumor Microenvironment | 1 | 2019 | 212 | 0.150 |
Why?
| Male | 9 | 2019 | 25241 | 0.140 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 377 | 0.140 |
Why?
| Neoplastic Cells, Circulating | 1 | 2017 | 74 | 0.140 |
Why?
| Epithelial Cells | 1 | 2018 | 209 | 0.140 |
Why?
| Cell Line | 4 | 2017 | 1000 | 0.140 |
Why?
| Lipopolysaccharides | 2 | 2008 | 192 | 0.140 |
Why?
| Umbilical Veins | 4 | 2010 | 23 | 0.140 |
Why?
| Enzyme Inhibitors | 1 | 2018 | 391 | 0.130 |
Why?
| Leukocytes | 3 | 2006 | 66 | 0.130 |
Why?
| Molecular Imaging | 1 | 2015 | 53 | 0.130 |
Why?
| Azides | 1 | 2014 | 9 | 0.120 |
Why?
| Fluorine Radioisotopes | 1 | 2014 | 24 | 0.120 |
Why?
| Tumor Burden | 2 | 2013 | 132 | 0.120 |
Why?
| Cell Transformation, Neoplastic | 2 | 2007 | 177 | 0.120 |
Why?
| Immunohistochemistry | 5 | 2020 | 973 | 0.120 |
Why?
| Interleukin-2 | 2 | 2021 | 72 | 0.120 |
Why?
| Drug Synergism | 2 | 2005 | 150 | 0.110 |
Why?
| Cell Adhesion | 3 | 2006 | 158 | 0.110 |
Why?
| Piperacillin | 1 | 2013 | 23 | 0.110 |
Why?
| Peptidomimetics | 1 | 2012 | 2 | 0.110 |
Why?
| Penicillanic Acid | 1 | 2013 | 20 | 0.110 |
Why?
| Agglutination Tests | 1 | 2012 | 5 | 0.110 |
Why?
| Allosteric Regulation | 1 | 2012 | 13 | 0.100 |
Why?
| Inflammation Mediators | 1 | 2013 | 112 | 0.100 |
Why?
| Cell Cycle | 1 | 2013 | 231 | 0.100 |
Why?
| Antimicrobial Cationic Peptides | 2 | 2008 | 28 | 0.100 |
Why?
| Up-Regulation | 2 | 2011 | 452 | 0.100 |
Why?
| Partial Pressure | 1 | 2011 | 14 | 0.100 |
Why?
| Metformin | 1 | 2012 | 64 | 0.100 |
Why?
| Neoplastic Stem Cells | 1 | 2012 | 103 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2011 | 51 | 0.090 |
Why?
| Fibroblasts | 1 | 2013 | 345 | 0.090 |
Why?
| Glutamine | 2 | 2024 | 171 | 0.090 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 119 | 0.090 |
Why?
| Cell Movement | 4 | 2006 | 247 | 0.090 |
Why?
| Spiro Compounds | 1 | 2010 | 8 | 0.090 |
Why?
| Cytokines | 1 | 2013 | 612 | 0.090 |
Why?
| Lignans | 1 | 2008 | 5 | 0.080 |
Why?
| Salmonella typhimurium | 1 | 2008 | 48 | 0.080 |
Why?
| Amino Acid Substitution | 1 | 2008 | 82 | 0.080 |
Why?
| Klebsiella pneumoniae | 1 | 2008 | 20 | 0.080 |
Why?
| Furans | 1 | 2008 | 26 | 0.080 |
Why?
| Surface Properties | 1 | 2007 | 72 | 0.070 |
Why?
| Escherichia coli | 1 | 2008 | 186 | 0.070 |
Why?
| Angiostatins | 2 | 2006 | 2 | 0.070 |
Why?
| Vascular Neoplasms | 1 | 2007 | 17 | 0.070 |
Why?
| Endotoxins | 1 | 2006 | 34 | 0.070 |
Why?
| Concept Formation | 1 | 2006 | 12 | 0.070 |
Why?
| Gram-Negative Bacteria | 1 | 2006 | 34 | 0.070 |
Why?
| Protein Structure, Secondary | 2 | 2003 | 72 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 87 | 0.070 |
Why?
| Genes, Synthetic | 1 | 2005 | 1 | 0.070 |
Why?
| Protein Engineering | 1 | 2005 | 18 | 0.070 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 225 | 0.060 |
Why?
| Cloning, Molecular | 1 | 2005 | 185 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 138 | 0.060 |
Why?
| Angiogenic Proteins | 1 | 2004 | 6 | 0.060 |
Why?
| Dietary Supplements | 1 | 2008 | 443 | 0.060 |
Why?
| Feasibility Studies | 1 | 2006 | 375 | 0.060 |
Why?
| Protein Unfolding | 1 | 2024 | 6 | 0.060 |
Why?
| Colonic Neoplasms | 1 | 2006 | 161 | 0.060 |
Why?
| Disulfides | 1 | 2024 | 17 | 0.060 |
Why?
| Diphtheria Toxin | 1 | 2004 | 4 | 0.060 |
Why?
| Histones | 1 | 2006 | 312 | 0.060 |
Why?
| Mutagenesis, Site-Directed | 1 | 2024 | 99 | 0.060 |
Why?
| Protein Folding | 1 | 2024 | 49 | 0.060 |
Why?
| Mammary Neoplasms, Animal | 1 | 2004 | 35 | 0.060 |
Why?
| Osmosis | 1 | 2003 | 3 | 0.060 |
Why?
| Infusion Pumps | 1 | 2003 | 13 | 0.060 |
Why?
| Plasminogen | 1 | 2003 | 2 | 0.060 |
Why?
| Circular Dichroism | 1 | 2003 | 41 | 0.060 |
Why?
| Serum Albumin | 1 | 2003 | 58 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 2 | 2004 | 1376 | 0.050 |
Why?
| Extracellular Matrix | 1 | 2003 | 111 | 0.050 |
Why?
| Immune Tolerance | 1 | 2022 | 96 | 0.050 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2008 | 828 | 0.050 |
Why?
| Reactive Oxygen Species | 1 | 2024 | 408 | 0.050 |
Why?
| Endostatins | 3 | 2007 | 4 | 0.050 |
Why?
| Neoplasm Invasiveness | 1 | 2022 | 267 | 0.050 |
Why?
| Immunity | 1 | 2021 | 35 | 0.050 |
Why?
| Immune System | 1 | 2021 | 44 | 0.050 |
Why?
| Ethers | 1 | 2021 | 8 | 0.050 |
Why?
| Regenerative Medicine | 1 | 2021 | 9 | 0.050 |
Why?
| Melanoma | 1 | 2004 | 285 | 0.050 |
Why?
| Tissue Scaffolds | 1 | 2021 | 33 | 0.050 |
Why?
| Angiogenesis Inducing Agents | 1 | 2000 | 8 | 0.050 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2020 | 184 | 0.050 |
Why?
| Tissue Engineering | 1 | 2021 | 64 | 0.040 |
Why?
| Adenocarcinoma | 1 | 2004 | 396 | 0.040 |
Why?
| Bone Marrow Cells | 1 | 2021 | 191 | 0.040 |
Why?
| Mice, Inbred C3H | 2 | 2012 | 83 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2004 | 1032 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2004 | 488 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 5 | 0.040 |
Why?
| Inflammation | 1 | 2022 | 604 | 0.040 |
Why?
| NAD | 1 | 2018 | 43 | 0.040 |
Why?
| Microcirculation | 2 | 2010 | 70 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2018 | 111 | 0.040 |
Why?
| Glutathione | 1 | 2019 | 295 | 0.040 |
Why?
| Microscopy, Fluorescence | 1 | 2018 | 162 | 0.040 |
Why?
| Phagocytosis | 1 | 2017 | 48 | 0.040 |
Why?
| Glycolysis | 1 | 2017 | 70 | 0.040 |
Why?
| Transplantation, Heterologous | 2 | 2008 | 74 | 0.030 |
Why?
| Clonal Anergy | 2 | 2006 | 13 | 0.030 |
Why?
| Extracellular Fluid | 1 | 2015 | 15 | 0.030 |
Why?
| Nitroimidazoles | 1 | 2015 | 15 | 0.030 |
Why?
| Microbubbles | 1 | 2015 | 25 | 0.030 |
Why?
| Cell Count | 1 | 2015 | 147 | 0.030 |
Why?
| Stromal Cells | 1 | 2015 | 72 | 0.030 |
Why?
| Pressure | 1 | 2015 | 105 | 0.030 |
Why?
| Paclitaxel | 2 | 2006 | 84 | 0.030 |
Why?
| Down-Regulation | 2 | 2006 | 348 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2015 | 144 | 0.030 |
Why?
| Radiochemistry | 1 | 2014 | 1 | 0.030 |
Why?
| Cycloaddition Reaction | 1 | 2014 | 1 | 0.030 |
Why?
| Click Chemistry | 1 | 2014 | 2 | 0.030 |
Why?
| Random Allocation | 1 | 2015 | 281 | 0.030 |
Why?
| Radiotherapy Dosage | 1 | 2015 | 244 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 151 | 0.030 |
Why?
| Recombinant Proteins | 2 | 2006 | 486 | 0.030 |
Why?
| Cell Differentiation | 1 | 2017 | 651 | 0.030 |
Why?
| Contrast Media | 1 | 2015 | 184 | 0.030 |
Why?
| Molecular Structure | 1 | 2014 | 297 | 0.030 |
Why?
| Ultrasonography | 1 | 2015 | 436 | 0.030 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2014 | 349 | 0.030 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 2012 | 8 | 0.030 |
Why?
| Adenylate Kinase | 1 | 2012 | 10 | 0.030 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2012 | 77 | 0.020 |
Why?
| Radiometry | 1 | 2012 | 123 | 0.020 |
Why?
| Rats | 2 | 2008 | 3305 | 0.020 |
Why?
| 4-Butyrolactone | 1 | 2008 | 5 | 0.020 |
Why?
| Butylene Glycols | 1 | 2008 | 14 | 0.020 |
Why?
| Phytoestrogens | 1 | 2008 | 22 | 0.020 |
Why?
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2008 | 51 | 0.020 |
Why?
| Receptors, Progesterone | 1 | 2008 | 63 | 0.020 |
Why?
| Ovariectomy | 1 | 2008 | 119 | 0.020 |
Why?
| Estrogen Receptor beta | 1 | 2008 | 54 | 0.020 |
Why?
| Estrogen Receptor alpha | 1 | 2008 | 89 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2007 | 22 | 0.020 |
Why?
| Carcinogens | 1 | 2008 | 199 | 0.020 |
Why?
| Horseshoe Crabs | 1 | 2006 | 3 | 0.020 |
Why?
| Blood Bactericidal Activity | 1 | 2006 | 4 | 0.020 |
Why?
| Lipid A | 1 | 2006 | 4 | 0.020 |
Why?
| Polymyxin B | 1 | 2006 | 5 | 0.020 |
Why?
| Neutralization Tests | 1 | 2006 | 24 | 0.020 |
Why?
| Cytidine | 1 | 2006 | 5 | 0.020 |
Why?
| Pyrroles | 1 | 2007 | 69 | 0.020 |
Why?
| DNA Modification Methylases | 1 | 2006 | 28 | 0.020 |
Why?
| Endotoxemia | 1 | 2006 | 32 | 0.020 |
Why?
| Acetylation | 1 | 2006 | 97 | 0.020 |
Why?
| Methylation | 1 | 2006 | 122 | 0.020 |
Why?
| Blood Proteins | 1 | 2006 | 82 | 0.020 |
Why?
| Chick Embryo | 1 | 2006 | 82 | 0.020 |
Why?
| Vimentin | 1 | 2006 | 32 | 0.020 |
Why?
| Nucleic Acid Hybridization | 1 | 2006 | 54 | 0.020 |
Why?
| Gene Silencing | 1 | 2006 | 119 | 0.020 |
Why?
| Cyclohexanes | 1 | 2006 | 4 | 0.020 |
Why?
| Zebrafish | 1 | 2006 | 54 | 0.020 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2006 | 53 | 0.020 |
Why?
| Transfection | 1 | 2007 | 354 | 0.020 |
Why?
| Histone Deacetylases | 1 | 2006 | 50 | 0.020 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 2006 | 36 | 0.020 |
Why?
| Pichia | 1 | 2005 | 8 | 0.020 |
Why?
| Gene Transfer Techniques | 1 | 2005 | 37 | 0.020 |
Why?
| Cyclophosphamide | 1 | 2006 | 165 | 0.020 |
Why?
| Neovascularization, Physiologic | 1 | 2005 | 68 | 0.020 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2004 | 48 | 0.020 |
Why?
| Membrane Proteins | 1 | 2006 | 341 | 0.010 |
Why?
| Indoles | 1 | 2007 | 278 | 0.010 |
Why?
| Treatment Outcome | 1 | 2014 | 5141 | 0.010 |
Why?
| Necrosis | 1 | 2004 | 176 | 0.010 |
Why?
| Antibodies | 1 | 2004 | 154 | 0.010 |
Why?
| Skin | 1 | 2007 | 409 | 0.010 |
Why?
| In Situ Nick-End Labeling | 1 | 2003 | 57 | 0.010 |
Why?
| Base Sequence | 1 | 2004 | 643 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 2003 | 144 | 0.010 |
Why?
| Epigenesis, Genetic | 1 | 2006 | 374 | 0.010 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 595 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2004 | 555 | 0.010 |
Why?
| RNA, Messenger | 1 | 2004 | 1105 | 0.010 |
Why?
| Endothelial Growth Factors | 1 | 2000 | 9 | 0.010 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2000 | 15 | 0.010 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2000 | 34 | 0.010 |
Why?
| Lymphokines | 1 | 2000 | 20 | 0.010 |
Why?
| Scrotum | 1 | 2000 | 30 | 0.010 |
Why?
| Interleukin-1 | 1 | 2000 | 104 | 0.010 |
Why?
| Models, Biological | 1 | 2002 | 727 | 0.010 |
Why?
| Breast Neoplasms | 1 | 2004 | 1174 | 0.010 |
Why?
|
|
Dings's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|